Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy
Eos Biosciences, Inc. , a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for Eos-001 , the company’s HER3-targeted Eosome with doxorubicin payload.
Omar Haffar , Ph.D., Founder, President and Chief Executive Officer, commented, “This is a very exciting time for Eos Biosciences. In addition to expanding and solidifying our patent portfolio, we are making very significant progress on the pre-clinical development and scale-up manufacturing of our products.” Dr. Haffar continued, “We are also implementing a strategic expansion of our product pipeline into immuno-oncology, and the application of Eosomes to other high impact disease areas, such as CNS. We expect to report positive progress in these and other areas in the near future.”
Eos-001 is a proof-of-concept proprietary product in preclinical development, intended to address Triple Negative Breast Cancer (TNBC) and HER2+ breast cancer resistant or nonresponsive to first line therapies. HER3 is over-expressed on TNBC and many types of HER2+ metastatic and drug-resistant solid tumors.
Eosomes are innovative self-assembling nanobiologic particles composed of a recombinant polypeptide and a therapeutic payload. The recombinant polypeptide is designed to incorporate three functional domains for cell targeting, active endosomal escape, and therapeutic payload binding. The modular design of the polypeptide provides significant versatility in adapting the application of the Eosomes to multiple disease areas and therapeutic modalities. To date, Eos has generated two forms of Eosomes, one targeting HER3 and one targeting c-Met. Expression of both cell surface receptors is upregulated on metastatic and drug-resistant solid tumors.
About Eos Biosciences, Inc.
Eos Biosciences Inc. is a bio-targeted nanomedicines company based in Los Angeles, California with a worldwide and exclusive license from Cedars-Sinai Medical Center to the intellectual property and know how covering the Eosomes drug-targeting and delivery platform technology.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PHARNEXT19.4.2018 17:47 | pressemeddelelse
Pharnext to Showcase PLEOTHERAPY™ R&D Platform at the 8th Annual Global Orphan Drug Conference
CA-MASIMO19.4.2018 17:03 | pressemeddelelse
New Study Investigates the Utility of Masimo SpHb® in Post-operative Red Blood Cell (RBC) Transfusion Best Practices
CA-SYNTERACT19.4.2018 16:08 | pressemeddelelse
Synteract Repositions Itself with Centers of Therapeutic Development and Unveils Updated Brand Platform
NEL-ASA19.4.2018 16:02 | pressemeddelelse
Nel ASA: Receives Additional Purchase Order from Nikola
VOITH19.4.2018 15:41 | pressemeddelelse
Voith and Franka Emika Form a Strategic Partnership
CA-ANDERSEN-TAX19.4.2018 15:32 | pressemeddelelse
Andersen Global Expands Presence in Portugal with CNA - Curado, Nogueira & Associados
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum